

## Discovery Pathway Advisory Group (DPAG)

- DPAG will offer independent and impartial support, advice and assessment to early translational projects and funding applications. Its primary purpose is to enhance:
  - The implementation of on-going early translational studies;
  - The quality of applications for early translational funding to schemes such as the UoM/MRC Confidence in Concept;
  - The success of follow-on funding applications and commercial development after proof-of-concept has been obtained.

## DPAG membership

- A virtual group that will allow us to readily identify individuals whose experience could help other academics working on drug, device or biomarker discovery facing activities and associated grant applications.
- Where appropriate this can also help us to utilise our wider networks, both within and outside of the University.
- When relevant projects come up Sam/Anu will contact specific individuals or the wider group to request peer review or advice.
- We can't promise to help... but we will try!
- January 2018 – over 30 individuals identified and contacted, current membership stands at 24 from across FMBH and FSE.


Name	Area/Key Words
Sam Butterworth	Medicinal chemistry, tool/lead identification strategy, general advice
Anu Suokas	Strategic Funding team
Pip Peakman	MCRC
Rick Watson	IP
Cat Headley	Unmet need, development pathway market access
Elaine Bignell	Antifungals
Mike Bromley	Antifungals
Lydia Tabernero	Structural Biology
Jeremy Derrick	Structural Biology
Doug Kell	Systems biology
Sally Freeman	Medicinal chemistry
Richard Bryce	Computational chemistry
Kaye Williams	In vivo models and dosing/formulation
Alex Galetin	Pharmacy: Pharmacokinetics/ADME
Leon Aarons	PKPD modeling
Alan Dickson	Cell lines, construct issues, biopharmaceuticals
Sarah Cartmell	Medicines and Materials
Kevin O'Brien	Clinical trial design
Andy Vail	Clinical trial design
Mohammed Zubair	Regulatory key issues strategy
Matthew Krebs	Clinical trials
Tony Freemont	Biomarker discovery
Katherine Boylan	Biomarker discovery
Curtis Dobson	Devices


Name	Area/Key Words
Sam Butterworth	Medicinal chemistry, tool/lead identification strategy, general advice
Anu Suokas	Strategic Funding team
Pip Peakman	MCRC
Rick Watson	IP
Cat Headley	Unmet need, development pathway market access
Elaine Bignell	Antifungals
Mike Bromley	Antifungals
Lydia Tabernero	Structural Biology
Jeremy Derrick	Structural Biology
Doug Kell	Systems biology
Sally Freeman	Medicinal chemistry
Richard Bryce	Computational chemistry
Kaye Williams	In vivo models and dosing/formulation
Alex Galetin	Pharmacy: Pharmacokinetics/ADME
Leon Aarons	PKPD modeling
Alan Dickson	Cell lines, construct issues, biopharmaceuticals
Sarah Cartmell	Medicines and Materials
Kevin O'Brien	Clinical trial design
Andy Vail	Clinical trial design
Mohammed Zubair	Regulatory key issues strategy
Matthew Krebs	Clinical trials
Tony Freemont	Biomarker discovery
Katherine Boylan	Biomarker discovery
Curtis Dobson	Devices


Therapeutics
Diagnostics
Devices
Digital health
Mixed?

# Small Molecule 4D Map

Even this is oversimplified relative to the complexities of an actual project...









There is more to successful translational applications than just have the right data and plan...

e.g. Line of Sight, TPPs, clinical vs statistical significance.

